Nanobac Pharmaceuticals Announces Availability of Diagnostic Testing Services
TAMPA, Fla., Oct 02, 2007 (BUSINESS WIRE) -- Nanobac Pharmaceuticals Inc. (OTCBB: NNBP) ("Nanobac" or "the Company") is pleased to announce that its diagnostic test, NB2, being offered through an agreement with American Health Associates (AHA) will be available by late October. Parties interested in getting tested are encouraged to start the specimen collection process as AHA is ready to receive NB2 specimens.
"We are extremely excited to make our diagnostic test available to patients and physicians in the United States as we had discussed in our investor conference call," stated Alex H. Edwards III, Director, Nanobac Pharmaceuticals. "This is the first step in creating awareness of the NB2 test's utility in the Diagnosis and Management of patients with a multitude of diseases, and is the start of acceptance as a standard of care in healthcare," Edwards concluded.
Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. Information on how to obtain an NB2 test is available at www.nanobac.com Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.
SOURCE: Nanobac Pharmaceuticals Inc.
CONTACT: Nanobac Pharmaceuticals, Tampa
Brady Millican, 813-264-2241
or
Redwood Consultants
Jens Dalsgaard, 415-884-0348
Copyright Business Wire 2007KEYWORD: United States
North America
Florida
INDUSTRY KEYWORD: Health
Infectious Diseases
Pharmaceutical
Other Health
SUBJECT CODE: Product/Service
|
